Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
about
FOXP3 ensembles in T-cell regulationTherapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammationPathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationTregs in infection and vaccinology: heroes or traitors?Modulation of GITR for cancer immunotherapyRegulatory T cell: a protection for tumour cellsMolecular control over thymic involution: from cytokines and microRNA to aging and adipose tissueTargeting regulatory T cells in cancerSuppression, subversion and escape: the role of regulatory T cells in cancer progressionIL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanomaCombined Immune Therapy for the Treatment of Visceral LeishmaniasisKey role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic targetSerum anti-BPAG1 auto-antibody is a novel marker for human melanomaAgonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunityGranzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice.Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Regulation of IL-2 gene expression by Siva and FOXP3 in human T cells.Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cellsAntibody-based immunotherapy for malignant glioma.Murine B cell development and antibody responses to model antigens are not impaired in the absence of the TNF receptor GITR.Cancer immunotherapy in clinical practice -- the past, present, and future.Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy.New roads open up for implementing immunotherapy in mesothelioma.Regulatory T cells suppress antigen-driven CD4 T cell reactivity following injury.The Serine Protease Inhibitor, 4-(2-aminoethyl) Benzene Sulfonyl Fluoride Hydrochloride, Reduces Allergic Inflammation in a House Dust Mite Allergic Rhinitis Mouse Model.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunityIntermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model
P2860
Q24299602-7B1752CC-8C63-4FF6-A42F-DEFBF3E62CD5Q24598725-18319DF6-96C1-4D0F-B7FA-E06ADEEF81F8Q26765345-5F9F12AC-1BDA-4AAF-B1F0-0C5ABED0A389Q26822874-AC5729D2-8B0E-4BF7-8413-8F8F4A658C94Q26853557-32B1375E-E6B6-48D4-BCBB-A716EA044DFBQ26991447-35BC8340-0CB4-47C0-AE93-DBDF10D56392Q27011835-E328C82D-C0A6-4FFF-A436-48EBE31CECD2Q27022348-A0322E35-655E-4CD7-8033-191DCDA06092Q27026151-B3D80FB1-90C6-4F3A-9872-39B75F94FC02Q28073154-B24DEC9B-DC95-4523-AF5C-768FEDB57FCFQ28307216-6C285D04-A583-4D74-9F83-CB37756F2CA3Q28550162-306E87F9-06C8-4736-9FEF-985683112181Q28750209-D737FD0B-361A-489F-99C5-E1C296F4F5D4Q30982790-94C766B7-D2DA-45CE-881C-1EDDB44F8F67Q33573450-206F0294-C85D-4D9E-AAA1-EEF24D98E898Q33657130-756CC9EB-E0F1-4517-AE98-22A3C194222FQ33706382-2B078496-9582-426D-8883-D9804433A3AAQ33814776-108132A3-236F-4D6D-A634-8F4932D02347Q33886184-19A877A7-9212-4229-BC05-91771D54108EQ33889105-DA87E1E9-93FF-4520-AC16-5060E08F8A4FQ33894831-382DCACE-4C89-4003-8B4D-CD9F9817F665Q33926200-51C4F203-E4D9-4B26-A214-409613F2DC21Q33968361-2AD0A061-7602-479A-BB50-8C72170F4666Q34020594-3544DCCE-7BB0-432E-9327-66A1BF0F93BBQ34033914-1A7E8CBA-CD78-499F-A63B-B8F55EF13177Q34076126-4CC452F6-F12C-496F-A969-E131451F4A21Q34120472-8E255DD7-B695-44A6-92B1-1DAA6CFDE91DQ34157345-7105EBA6-D07C-410A-BC30-1A8CF9D68C41Q34309399-885F4D4D-DCC8-491E-AD2E-ED1697551195Q34326006-45420948-5153-4090-8E37-9E80BA559CBAQ34331993-E33574A5-FEFA-42C5-BD41-303BCE77175EQ34417516-E0D421A9-1709-437F-ACC9-B7DB7E131122Q34429730-737ED6E7-9C56-401C-B392-683211B0B339Q34477650-AEE3C8B7-2771-4DBB-885B-A940F16F5E71Q34591128-69796151-5C57-40AB-972B-9EE9D06B0F50Q34633278-2B87A816-2417-4D17-9C90-CE9EE3902B36Q34634220-02399CBF-A846-40F7-AF65-F51A99CF22A7Q34984596-834D4D5F-68E2-4E26-A1EF-B256BFC14CEAQ35051306-3FF06D58-6D45-43FB-83D8-1F4154DE1F94Q35136266-8E3E9DAE-A784-4DE6-B5DC-5D0ED397C0E5
P2860
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Treatment of advanced tumors w ...... +CD25+CD4+ regulatory T cells.
@ast
Treatment of advanced tumors w ...... +CD25+CD4+ regulatory T cells.
@en
type
label
Treatment of advanced tumors w ...... +CD25+CD4+ regulatory T cells.
@ast
Treatment of advanced tumors w ...... +CD25+CD4+ regulatory T cells.
@en
prefLabel
Treatment of advanced tumors w ...... +CD25+CD4+ regulatory T cells.
@ast
Treatment of advanced tumors w ...... +CD25+CD4+ regulatory T cells.
@en
P2093
P2860
P356
P1476
Treatment of advanced tumors w ...... 3+CD25+CD4+ regulatory T cells
@en
P2093
Jun Shimizu
Kuibeom Ko
Kyoko Nakamura
Sayuri Yamazaki
Shimon Sakaguchi
Takashi Nomura
Tomohisa Nishioka
Tsutomu Chiba
P2860
P304
P356
10.1084/JEM.20050940
P407
P577
2005-09-26T00:00:00Z